Journal of Immigrant and Minority Health

, Volume 17, Issue 1, pp 79–88

Development and Initial Testing of Messages to Encourage Tuberculosis Testing and Treatment Among Bacille Calmette-Guerin (BCG) Vaccinated Persons

  • Joan M. Mangan
  • Sebastian Galindo-Gonzalez
  • Tracy A. Irani
Original Paper
  • 174 Downloads

Abstract

Misperceptions surrounding the Bacille Calmette-Guerin (BCG) vaccine can lead some vaccinated individuals to resist being tested and treated for tuberculosis (TB). Educational messages to best explain the risk of TB to BCG-vaccinated, Hispanic persons were systematically developed and tested. First, TB program staff provided messages they considered effective. These were analyzed and validated by TB experts, and then presented in group interviews initially to foreign-born Hispanic persons with a TB diagnosis, and then persons without a prior TB diagnosis. Based on interviewees’ feedback, preferred statements were used to develop one long and three short comprehensive messages. One-on-one interviews were conducted with Hispanic persons to assess the saliency of the comprehensive educational messages. Participants preferred messages that were gain or positively-framed and explained that BCG does not confer lifelong protection against TB. Participants confirmed the messages would likely have a positive impact on patient decisions to undergo TB testing and treatment.

Keywords

Tuberculosis BCG vaccine Health beliefs Patient education Message development 

References

  1. 1.
    Michaels C, McEwen MM, McArthur DB. Saying “no” to professional recommendations: client values, beliefs, and evidence-based practice. J Am Acad Nurse Pract. 2008;20(12):585–9.PubMedCrossRefGoogle Scholar
  2. 2.
    McEwen MM, Boyle JS. Resistance, health, and latent tuberculosis infection: Mexican immigrants at the US-Mexico border. Res Theory Nurs Pract. 2007;21(3):185–97.PubMedCrossRefGoogle Scholar
  3. 3.
    Alvarez-Gordillo GC, et al. Perceptions and practices related with tuberculosis and treatment compliance in Chiapas, Mexico. Salud Publica Mex. 2000;42(6):520–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Mata JI. Integrating the client’s perspective in planning a tuberculosis education and treatment program in Honduras. Med Anthropol. 1985;9(1):57–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Armijos RX, et al. The meaning and consequences of tuberculosis for an at-risk urban group in Ecuador. Rev Panam Salud Publica. 2008;23(3):188–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Kaona FA, et al. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health. 2004;4:68.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Rubel AJ, Garro LC. Social and cultural factors in the successful control of tuberculosis. Public Health Rep. 1992;107(6):626–36.PubMedCentralPubMedGoogle Scholar
  9. 9.
    CDC. Reported Tuberculosis in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, CDC, October 2012. Retrieved 4 Feb 2013, from http://www.cdc.gov/tb/statistics/reports/2011/pdf/report2011.pdf.
  10. 10.
    Case DO, et al. Avoiding versus seeking: the relationship of information seeking to avoidance, blunting, coping, dissonance, and related concepts. J Med Libr Assoc. 2005;93(3):353–62.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Shiloh S, et al. Being ‘at-risk’ for developing cancer: cognitive representations and psychological outcomes. J Behav Med. 2009;32(2):197–208.PubMedCrossRefGoogle Scholar
  12. 12.
    Centers for Disease Control and Prevention. Trends in Tuberculosis: United States, 2008. MMWR. 2009;58(10):249–53.Google Scholar
  13. 13.
    Griffin R, Young D: The future of tuberculosis vaccinology. In Raviglione MC, ed. Reichman and Hershfield’s Tuberculosis A comprehensive, international approach. Third Edition, Part B. New York: Informa Healthcare USA, Inc.; 2006: 1153–1168.Google Scholar
  14. 14.
    Centers for Disease Control and Prevention: BCG vaccine Factsheet. (1 Jun 2009). Retrieved 27 Sept 2009, from http://www.cdc.gov/tb/publications/factsheets/prevention/BCG.htm.
  15. 15.
    Farer LS. Tuberculosis-a continuing problem. Am Rev Respir Dis. 1986;134(1):2–3.PubMedGoogle Scholar
  16. 16.
    Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J. 1977;2(6082):293–5.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Comstock GW, Palmer CE. Long term results of BCG vaccination in the Southern United States. Am Rev Respir Dis. 1966;93(2):171–83.PubMedGoogle Scholar
  18. 18.
    Tuberculosis Prevention Trial. Trial of BCG vaccines in South India for tuberculosis prevention: first report. Bull World Health Organ. 1979;57(5):819–27.Google Scholar
  19. 19.
    Public Health Laboratory Service Communicable Disease Surveillance Centre. BCG vaccination. Br Med J (Clin Res Ed). 1983;286:876–7.CrossRefGoogle Scholar
  20. 20.
    Watson JC, et al: Measles, Mumps, and Rubella—Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 1998; 47(RR-8); 1–57.Google Scholar
  21. 21.
    Poss JE. The meanings of tuberculosis for Mexican migrant farm workers in the United States. Soc Sci Med. 1998;47(2):195–202.PubMedCrossRefGoogle Scholar
  22. 22.
    Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis. 1998;2(3):200–7.PubMedGoogle Scholar
  23. 23.
    Fine PE. BCG: the challenge continues. Scand J Infect Dis. 2001;33(4):243–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Romano M, Huygen K. An update on vaccines for tuberculosis: there is more to it than just waning of BCG efficacy with time. Expert Opin Biol Ther. 2012;12(12):1601–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Piñeiro R, et al. Tuberculin skin test in bacille Calmette–Guérin-vaccinated children: how should we interpret the results? Eur J Paediatr. 2012;171(11):1625–32.CrossRefGoogle Scholar
  26. 26.
    Strecher VJ, Rosenstock IM. The health belief model. In: Glanz K, Lewis FM, Rimer BK, editors. Health behavior and health education: theory, research, and practice. 2nd ed. San Francisco: California Jossey-Bass Inc.; 1997. p. 41–59.Google Scholar
  27. 27.
    Petty RE, Cacioppo JT. The elaboration likelihood model of persuasion. In: Berkowitz L, editor. Advances in experimental and social psychology. New York: Academic Press; 1986. p. 123–205.Google Scholar
  28. 28.
    Petty RE, Cacioppo JT. Attitudes and persuasion: classic and contemporary approaches. Dubuque, IA: William C. Brown Co; 1981.Google Scholar
  29. 29.
    Ben-Nun P. Respondent fatigue. In: Lavrakas P, editor. Encyclopedia of survey research methods. Thousand Oaks: SAGE Publications, Inc.; 2008. p. 743–4.Google Scholar
  30. 30.
    Glanz K, Rimer BK: Theory at a Glance: Application to Health Promotion and Health Behavior (Second Edition) National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. NIH Pub. No. 05-3896 Washington, DC: NIH; Sept 2005.Google Scholar
  31. 31.
    Rothman AJ, Salovey P. Shaping perceptions to motivate healthy behavior: the role of message framing. Psychol Bull. 1997;121(1):3–19.PubMedCrossRefGoogle Scholar
  32. 32.
    World Health Organization: Global tuberculosis report 2012. Retrieved 25 Mar 2013 from http://www.who.int/tb/publications/global_report/gtbr12_main.pdf.
  33. 33.
    Zwerling A, et al. TB screening in Canadian health care workers using interferon-gamma release assays. PLoS ONE. 2012;7(8):e43014.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Rangaka MX, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Doberne D, Gaur RL, Banaei N. Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection. J Clin Microbiol. 2011;49(8):3061–4.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York (Outside the USA) 2013

Authors and Affiliations

  • Joan M. Mangan
    • 1
  • Sebastian Galindo-Gonzalez
    • 2
  • Tracy A. Irani
    • 2
  1. 1.Division of Tuberculosis EliminationCenters for Disease Control and PreventionAtlantaUSA
  2. 2.Department of Agricultural Education and CommunicationUniversity of FloridaGainesvilleUSA

Personalised recommendations